Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (371-380 of 441) with videos related to

Pageof 45
Sort By:
Journal of Hepatology|February 24, 2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersDonald Jensen, Kenneth E Sherman, Christophe Hézode, et al.
Gut|April 5, 2018
Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virusAlba Llibre, Yusuke Shimakawa, Estelle Mottez, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 24, 2017
Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimensK Rajender Reddy, Stanislas Pol, Paul J Thuluvath, et al.
Journal of Hepatology|June 7, 2014
Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infectionMelissa E Laird, Amira Mohsen, Darragh Duffy, et al.
Virology|June 6, 2012
Production of hepatitis B defective particles is dependent on liver statusFrancois Redelsperger, Bouchra Lekbaby, Yassmina Mandouri, et al.
Antioxidants (Basel, Switzerland)|February 25, 2022
Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort)Tangui Barré, Hélène Fontaine, Stanislas Pol, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Plos One|June 4, 2016
In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin LymphomasDanielle Canioni, Jean-Marie Michot, Pascaline Rabiega, et al.
BMC Infectious Diseases|August 11, 2016
Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigenGonzague Jourdain, Nicole Ngo-Giang-Huong, Tim R Cressey, et al.
Pageof 45

Showing results (371-380 of 441) with videos related to

Sort By:
Pageof 45
Journal of Hepatology|February 24, 2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersDonald Jensen, Kenneth E Sherman, Christophe Hézode, et al.
Gut|April 5, 2018
Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virusAlba Llibre, Yusuke Shimakawa, Estelle Mottez, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 24, 2017
Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimensK Rajender Reddy, Stanislas Pol, Paul J Thuluvath, et al.
Journal of Hepatology|June 7, 2014
Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infectionMelissa E Laird, Amira Mohsen, Darragh Duffy, et al.
Virology|June 6, 2012
Production of hepatitis B defective particles is dependent on liver statusFrancois Redelsperger, Bouchra Lekbaby, Yassmina Mandouri, et al.
Antioxidants (Basel, Switzerland)|February 25, 2022
Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort)Tangui Barré, Hélène Fontaine, Stanislas Pol, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Plos One|June 4, 2016
In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin LymphomasDanielle Canioni, Jean-Marie Michot, Pascaline Rabiega, et al.
BMC Infectious Diseases|August 11, 2016
Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigenGonzague Jourdain, Nicole Ngo-Giang-Huong, Tim R Cressey, et al.
Pageof 45